Randomized non-inferiority trial of Bicalutamide and Dutasteride versus LHRH agonists for prostate volume reduction prior to I-125 permanent implant brachytherapy for prostate cancer-Reference-Cited by-同舟云学术

Randomized non-inferiority trial of Bicalutamide and Dutasteride versus LHRH agonists for prostate volume reduction prior to I-125 permanent implant brachytherapy for prostate cancer

Published:2016-01 Issue:1 Volume:118 Page:141-147
ISSN:0167-8140
Container-title:Radiotherapy and Oncology
language:en
Short-container-title:Radiotherapy and Oncology

Author:

Gaudet Marc,Vigneault Éric^ORCID,Foster William,Meyer François,Martin André-Guy

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology

Reference29 articles.

1. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients;Keyes;Int J Radiat Oncol Biol Phys,2009

2. Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy;Mabjeesh;Urology,2007

3. Androgen deprivation-mediated cytoreduction before interstitial brachytherapy for prostate cancer does not abrogate the elevated risk of urinary morbidity associated with larger initial prostate volume;Petit;Brachytherapy,2007

4. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy;Davis;Brachytherapy,2012

5. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013;Heidenreich;Eur Urol,2014

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms, mitigation, and management of urinary toxicity from prostate radiotherapy;The Lancet Oncology;2022-12

2. Permanent interstitial brachytherapy for prostate cancer implementing neoadjuvant prostatic artery embolization;Brachytherapy;2022-05

3. GEC-ESTRO ACROP prostate brachytherapy guidelines;Radiotherapy and Oncology;2022-02

4. Low dose rate brachytherapy for primary treatment of localized prostate cancer: A systemic review and executive summary of an evidence-based consensus statement;Brachytherapy;2021-11

5. A prospective clinical and transcriptomic feasibility study of oral‐only hormonal therapy with radiation for unfavorable prostate cancer in men 70 years of age and older or with comorbidity;Cancer;2021-04-21